Tango Therapeutics, Inc.

Tango Therapeutics, Inc. (Nasdaq: TNGX) is a precision oncology biopharmaceutical company that entered the public markets through a business combination with BCTG Acquisition Corp., a blank-check company sponsored by BCTG Holdings LLC, an entity affiliated with BVF Partners L.P. The SPAC completed its IPO in 2020 and targeted the healthcare and biotechnology sector. Tango Therapeutics develops cancer therapies using a synthetic lethality approach, seeking to exploit genetic vulnerabilities in tumor cells. The company filed this Form 10-Q with the SEC on May 14, 2021, under accession number 0001213900-21-026397, reflecting its status as a publicly reporting biotechnology company following the de-SPAC transaction. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics on TNGX and the broader SPAC universe.